Literature DB >> 32488607

Acute Metabolic Emergencies in Diabetes: DKA, HHS and EDKA.

Muhammad Muneer1, Ijaz Akbar2.   

Abstract

Emergency admissions due to acute metabolic crisis in patients with diabetes remain some of the most common and challenging conditions. DKA (Diabetic Ketoacidosis), HHS (Hyperglycaemic Hyperosmolar State) and recently focused EDKA (Euglycaemic Diabetic Ketoacidosis) are life-threatening different entities. DKA and HHS have distinctly different pathophysiology but basic management protocols are the same. EDKA is just like DKA but without hyperglycaemia. T1D, particularly children are vulnerable to DKA and T2D, particularly elderly with comorbidities are vulnerable to HHS. But these are not always the rule, these acute conditions are often occur in different age groups with diabetes. It is essential to have a coordinated care from the multidisciplinary team to ensure the timely delivery of right treatment. DKA and HHS, in many instances can present as a mixed entity as well. Mortality rate is higher for HHS than DKA but incidences of DKA are much higher than HHS. The prevalence of HHS in children and young adults are increasing due to exponential growth of obesity and increasing T2D cases in this age group. Following introduction of SGLT2i (Sodium-GLucose co-Transporter-2 inhibitor) for T2D and off-label use in T1D, some incidences of EDKA has been reported. Healthcare professionals should be more vigilant during acute illness in diabetes patients on SGLT2i without hyperglycaemia to rule out EDKA. Middle aged, mildly obese and antibody negative patients who apparently resemble as T2D without any precipitating causes sometime end up with DKA which is classified as KPD (Ketosis-prone diabetes). Many cases can be prevented by following 'Sick day rules'. Better access to medical care, structured diabetes education to patients and caregivers are key measures to prevent acute metabolic crisis.

Entities:  

Keywords:  ARDS (Acute Respiratory Distress Syndrome); Anion gap; CSII (Continuous Subcutaneous Insulin Infusion); Cerebral Oedema; Fixed Rate Intravenous Insulin Infusion (FRIII); Hypokalaemia; Osmolality; Variable Rate Intravenous Insulin Infusion (VRIII)

Mesh:

Substances:

Year:  2021        PMID: 32488607     DOI: 10.1007/5584_2020_545

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  5 in total

1.  Epidemiology, Risk Factors and Etiology of Altered Level of Consciousness Among Patients Attending the Emergency Department at a Tertiary Hospital in Mogadishu, Somalia.

Authors:  Hassan Adan Ali; Mohamed Farah Yusuf Mohamud
Journal:  Int J Gen Med       Date:  2022-05-30

2.  Acute esophageal necrosis complicating diabetic ketoacidosis in a patient with type II diabetes mellitus and excessive cola consumption: a case report.

Authors:  Despoina Avramidou; Paraskevi Violatzi; Dimitra-Georgia Zikoudi; Anil Mourseloglou; Stefanos Panagaris; Eleni Metaxa; Anestis Partsalidis; Ioannis Feresiadis; Christakis Savva; Vasileios Papadopoulos
Journal:  Diabetol Int       Date:  2021-08-27

3.  Severe hypernatremia in soft drink ketoacidosis and hyperglycemic hyperosmolar state at the onset of type 2 diabetes mellitus: a case series of three adolescents.

Authors:  Soo Jeong Choo; Hyun Gyung Lee; Chan Jong Kim; Eun Mi Yang
Journal:  Clin Pediatr Endocrinol       Date:  2022-02-16

4.  Cardiac Biomarkers and Risk Scores in Relation with History of Atherosclerotic Cardiovascular Disease in Patients Admitted with COVID-19: The Experience of an Eastern European Center.

Authors:  Catalina Lionte; Victorita Sorodoc; Raluca Ecaterina Haliga; Cristina Bologa; Alexandr Ceasovschih; Oana Sirbu; Victoria Gorciac; Andrei-Costin Chelariu; Alexandra Stoica; Roxana Elena Tocila; Minerva Codruta Badescu; Irina-Iuliana Costache; Christiana Brigitte Sandu; Elisabeta Jaba; Laurentiu Sorodoc
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

Review 5.  Hypokalemia in Diabetes Mellitus Setting.

Authors:  Lucas Coregliano-Ring; Kleber Goia-Nishide; Érika Bevilaqua Rangel
Journal:  Medicina (Kaunas)       Date:  2022-03-16       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.